PharmaCyte Biotech Releases HealthWatch Segment Featured on Discovery Channel
June 30 2015 - 8:30AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that its technology and
treatments were featured on the Discovery Channel and ION Network
this morning. Discovery Channel and ION Network’s news magazine
series, “NewsWatch,” aired the company’s story in a 3:42
“HealthWatch” segment that highlighted the companies efforts to
bring both cancer and diabetes treatments to market.
For those who were unable to watch the segment
on Discovery Channel or ION Netowork, here is the link to view it:
https://www.youtube.com/watch?v=pqorMR_yEZQ.
PharmaCyte Biotech’s Chief Executive Officer,
Kenneth L. Waggoner, commented on the company getting nationwide
attention, “HealthWatch did a thorough job telling our story with
the level of enthusiasm and attention to detail that PharmaCyte
Biotech embraces in everything it does. We are extremely pleased
that as many as 96 million households in the U.S. have had an
opportunity to learn of our unique technology. The key to our
success is having our story told in a way that will facilitate
getting our treatments to patients who so desperately need
them.”
Each edition of NewsWatch, a source for breaking
consumer, technology, travel, health and entertainment news since
1990, reaches more than 96 million U.S. households. To date, over
700 million people have viewed the NewsWatch series, making it one
of the most successful independently produced news magazines on
television.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company focused on developing and
preparing to commercialize treatments for cancer and diabetes based
upon a proprietary cellulose-based live cell encapsulation
technology known as Cell-in-a-Box®. This unique and patented
technology will be used as a platform upon which treatments for
several types of cancer, including advanced, inoperable pancreatic
cancer, and diabetes are being built. PharmaCyte Biotech's
treatment for pancreatic cancer involves low doses of the
well-known chemotherapy prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or "cancer-killing" form. These capsules are placed as close to the
tumor as possible to enable the delivery of the highest levels of
the cancer-killing drug at the source of the cancer. This "targeted
chemotherapy" has proven remarkably effective in past clinical
trials. PharmaCyte Biotech is also working towards improving the
quality of life for patients with advanced pancreatic cancer and on
treatments for other types of solid cancerous tumors.
In addition, PharmaCyte Biotech is developing
treatments for cancer based upon chemical constituents of the
Cannabis plant, known as cannabinoids. In doing so, PharmaCyte
Biotech is examining ways to exploit the benefits of Cell-in-a-Box®
technology in optimizing the anticancer effectiveness of
cannabinoids, while minimizing or outright eliminating the
debilitating side effects usually associated with cancer
treatments. This provides PharmaCyte Biotech the rare opportunity
to develop “green” approaches to fighting deadly diseases, such as
cancer of the pancreas, brain and breast, which affect hundreds of
thousands of individuals worldwide every year.
Safe HarborThis press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte Biotech or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte Biotech, could cause actual
results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte Biotech’s
intellectual property and PharmaCyte Biotech’s continued ability to
raise capital. PharmaCyte Biotech does not assume any obligation to
update any of these forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com